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Abstract
Development of resistance to malaria treatments remains a great threat to
continued malaria burden reduction and elimination. Quantifying the impact
of key factors which increase the emergence and spread of drug resistance
can guide intervention strategies. Whilst modelling provides a framework to
understand these factors, we show that a simple of model with a sensitive–
resistant dichotomy leads to incorrectly focusing on reducing the treatment
rate as a means to prevent resistance. Instead we present a model that
considers the development of resistance within hosts as a scale, and we then
quantify the number of resistant infections that would arise from a single
sensitive infection. By including just one step before full resistance, the model
highlights that disrupting this development is more effective than reducing
treatment rate. This result is compounded when the model includes the more
realistic scenario of several intermediary steps. An additional comparison
to transmission probabilities, where resistant infections are less likely to be
transmitted (cost of resistance), confirms that preventing the establishment
of resistance is more effective than controlling the spread. Our work strongly
advocates for further studies into within-host models of resistance, including
the potential of combination therapies to disrupt emergence.
Keywords: Ross-MacDonald model, malaria treatment, resistance
emergence, resistance spread, resistance establishment, mutation
1. Introduction1
Resistance threatens not just control of malaria but also our potential to2
eliminate malaria in low prevalence settings. Several historical examples of3
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development of the spread of resistance to malaria treatment exist, such as4
widespread chloroquine resistance and less geographically spread sulfadox-5
ine/pyrimethamine resistance, and more recently, resistance to artemisinin6
(Yeung, 2004, WHO, 2018). Even once a drug is no longer in use, the resis-7
tant genotypes may decline slowly, or even persist indefinitely (Liechti et al.8
2017).9
In the early 2000s combination therapy, where an infected individual is10
treated with two or more drugs, became accepted as an approach to prevent11
resistance to a given particular drug given as monotherapy (World Health12
Organization 2001). Artemisinin combination therapies were introduced with13
short-acting artemisinin derivatives formulated with different longer-acting14
partner drugs, such lumefantrine or Mefloquine (Nosten and White 2007).15
Nonetheless, resistance continues to occur, with artemisinin resistance devel-16
oping in South East Asia (Me´nard et al. 2016) with fear of further spread-17
ing and thus threatening both morbidity control and elimination of malaria.18
More recently triple combination therapies with the view to delay emergence19
and spread are being tested (Shanks et al. 2014). The community state20
that to eliminate malaria policy decisions need to be preemptive, not reac-21
tive (Boni et al. 2016). This requires a deeper understanding of resistance22
which cannot be gained from generalisations of specific case studies. To test23
and understand key drivers of resistance, mathematical models provide an24
invaluable framework.25
zur Wiesch et al. (2011) consider the overall dynamics, and discuss which26
factors could influence the growth of resistance, including mutation, recom-27
bination and de novo versus transmitted resistance. Typically reducing the28
probability that de novo resistance mutations occur is often the focus, mean-29
ing that pathogens are rapidly eliminated and patients continue treatment30
after they feel better. However, Read et al. (2011) argue that the more ag-31
gressive the regime, the greater the selection pressure in favour of resistance.32
Essentially, reducing resistance is a balance between reducing the probability33
of de novo resistance whilst not creating opportunity for mutated genotypes34
to grow rapidly (Day and Read 2016). Kouyos et al. (2014) relate this bal-35
ance to high and low transmission areas, advising moderate treatment where36
malaria has high-transmission since co-infection is more frequent, and thus37
resistant and sensitive strains compete more often within an individual host.38
Aggressive treatment would be more likely to cause the removal of a sensi-39
tive competitor. In a summary of population genetics and epidemiological40
models for drug resistance, Mackinnon (2005) states that the two overriding41
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factors are the proportion of humans treated with drugs, and the efficacy of42
the drug in clearing parasites.43
When drug concentration is low enough to kill the sensitive genotype,44
it may not necessarily be high enough to kill partially-resistant mutations.45
With more uninfected blood cells, partially-resistant and resistant genotypes46
can multiply rapidly. This selection process is often summarised by the47
selection coefficient, which is simply the difference between the growth rate48
of the mutant type and the sensitive type for a given drug concentration - the49
relative fitness (Huijben et al. 2011). So a large selection coefficient implies50
that the mutant type is growing rapidly. Day et al. (2015) contend that51
instead of the relative fitness, the absolute fitness is a better measure. That52
is, the growth rate of the mutant type is compared to itself at a baseline rate53
defined by both the drug concentration and a within patient state variable,54
such as the density of resources, or immune cells.55
Having established that a resistant infection develops within a host, the56
transmission of this infection throughout the homogeneous population can57
be modelled via a compartment model. The most well-known example of a58
compartmental model for malaria transmission is the Ross-MacDonald model59
(Ross 1911, Macdonald 1957, Dietz 1974). This model puts the main burden60
of transmission on mosquito-specific features, and thus motivated mosquito-61
based malaria control programmes (Mandal et al. 2011). The simplicity62
and relevance of the Ross-MacDonald has ensured that it continues to be a63
strong basis for a broader theory of mosquito-bourne disease transmission64
and control (Smith et al. 2012).65
There are several compartmental models that include a treated popula-66
tion, and a population resistant to treatment. We compare our model to67
six models which we are aware of, see Table 1. Two of the models, Koella68
and Antia (2003) and Chiyaka et al. (2009), include an immune population.69
As expected, the three models which explicitly include a treated population70
(Koella and Antia (2003), Esteva et al. (2009) and Chiyaka et al. (2009))71
find that the proportion treated has an effect on the spread of drug resis-72
tance. The models of Koella and Antia (2003) and Esteva et al. (2009)73
also find that the spread of resistant infections depends on the effectiveness74
of the treatment (defined in terms of the period of infection), and the cost75
of resistance (defined in terms of the reduction of intensity of transmission76
due to mutation). Their models do not indicate transmission as a significant77
factor. Chiyaka et al. (2009) also show that the spread of drug resistance78
depends on the infectious periods, defined here as the ratio of the infectious79
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periods of treated and untreated humans. Unlike Koella and Antia (2003)80
and Esteva et al. (2009), Chiyaka et al. (2009) find the transmission rates81
from infectious humans with resistant and sensitive infections to influence82
the spread of resistant infections. Tumwiine et al. (2014) and Tchuenche et83
al (2014) show that as the evolution of drug resistance grows, so does the84
number of infections in the population. However, these models do not con-85
sider the transmission of resistant infections - mosquitoes are either infected86
or susceptible only such that resistance only occurs from evolution within a87
treated host. More recently, Legros and Bonhoeffer (2016) modelled the resis-88
tance within-host, and used this model to determine the transmission rates89
in a simple compartmental (susceptible-infected) model. Unlike the other90
models in Table 1, there is not a separation of hosts infected with sensitive91
or resistant infections, since resistance is incorporated in the transmission92
rates, which depend on the within-host model of the density of gametocytes.93
Generally, compartmental models which explicitly include a resistant94
class, do not include a partially-resistant class, although field evidence sug-95
gests that assuming only sensitive and fully-resistant gene classes is often96
invalid (Hastings et al. 2002). Resistance is a process, and thus better repre-97
sented as a scale than a dichotomy. Tchuenche et al (2014), who do include98
partial resistance, do not include this class within the mosquito population,99
and thus ignoring the transmission of partially resistant infections. This is100
particularly relevant when considering the spread of resistance.101
To summarise the overall findings of the compartmental models in Ta-102
ble 1, drug resistance increases in the population as treatment increases, and103
decreases as the period of infection decreases (drug efficacy increases). This104
is agreement with Mackinnon’s (2005) summary on population genetics and105
epidemiological models. When the evolution of drug resistance is included,106
it is found to be a driving factor, but a comparison of this factor to the107
transmission probabilities of sensitive and resistant infections is currently108
missing. This omission has become more important as recent work interfaces109
within-host models with population models via these probabilities (Legros110
and Bonhoeffer, 2016 and Bushman et al., 2018).111
This paper presents a novel compartmental model that includes the evo-112
lution of an infection within a treated host, such that a sensitive infection113
becomes a partially resistant infection, which becomes a fully resistant in-114
fection. This transference is defined by the ‘replacement rate’. The replace-115
ment rate is a summary statistic that could be interpreted as an evolution116
rate which leads to the emergence of resistance. There has been a variety of117
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approaches to model the emergence of resistance (Day et al., 2015, Day et al,118
2016, Hastings, 2003, Hastings and Hodel, 2014, Hastings et al., 2002, Hast-119
ings and Watkins, 2005, MacKinnon, 2005, Read et al. 2011, Stepniewska120
and White, 2008, zur Weisch et al., 2011). In Section 4 we demonstrate121
how three different approaches can be combined with our model to interface122
within host models with population models.123
Since ‘replacement rate’ is a summary statistic, it’s definition is flexible124
to the question at hand, and thus the definition of partial resistance. For125
example, when treatment is a combination of two drugs - partial resistance126
may represent that the host has developed resistance to one drug, but not127
the second. Alternatively, resistance may require several mutations, as is128
the case with sulphadoxine pyrimethamine which has five important point129
mutations that have been found to be associated with resistance (Sarmah130
et al., 2017). These mutations occur incrementally, and thus less than five131
mutations can be considered as partial resistance. In fact, instead of one132
level of partial resistance, the model could be adapted to have four levels133
of partial resistance, one for each mutation. See Subsection 3.4 for further134
discussion about increasing the number of partially resistant classes.135
In this model, the three different classes of infections are passed to mosquitoes136
such that mosquitoes can transmit partially resistant and fully resistant in-137
fections, where different classes of infections have different probabilities of138
being transmitted due to a cost of resistance. The key contribution of this139
paper is that we quantify the great importance of understanding the evolu-140
tion of drug resistance - the replacement rate. Comparing this replacement141
rate to transmission properties, we show that controlling the emergence of142
drug resistance within a host is more effective than controlling the spread.143
Our model compliments current research on resistance since it is this144
precise replacement rate that other research attempts to quantify, either145
by pharmacokinetic/pharmacodynamic modeling analysis (Hastings et al.146
2002), theoretical modelling (Day and Read 2016), or within-host models147
(Bushman et al. 2016). The interface between this research and our model is148
discussed more in Section 4. Our model suggests that in areas of high trans-149
mission, the effect of the replacement rate is greater, so it is more important150
to minimise it by, for example, using drugs with a short half life (Hastings151
et al. 2002).152
We do not include factors such as age structure, socio-economic factors,153
and migration since a malaria model that incorporates all factors and vari-154
ables becomes an overwhelmingly complex system (Mandal et al. 2011).155
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Moreover, our aim is to quantify the effect of treatment, and highlight what156
treatment and resistance variables are of most importance, so we include157
the minimum factors required. This is an introductory model that can act158
as the foundation for further studies which include multiple infections, and159
immunity.160
Table 1: The human and mosquito compartments used by previous malaria transmission
models which include a resistant population: Koella and Antia (2003), K, Esteva et al.
(2009), E, Chiyaka et al. (2009), C; Legros and Bonhoeffer (2011) (where immunity is
modelled within host - denoted by *); Tchuenche et al. (2011); Tumwiine et al. (2014);
and this paper, LP. All models include a susceptible population of humans and mosquitoes,
omitted from the table for clarity.
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K X X X X X X X
E X X X X X
C X X X X X X X X X
L X X∗ X
Tc X X X X X X X X X
Tu X X X X
LP X X X X X X X X X X X X
2. The model161
The model is based on the Ross-McDonald delay differential equation162
model (Ross 1911, Macdonald 1957) where populations of humans and mosquitoes163
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are either susceptible or infected. Infected mosquitoes bite susceptible hu-164
mans who then become infected. Mosquitoes which bite infected humans165
become exposed (infected but not infectious), and after τˆ time, become in-166
fectious if they have not already recovered. It is assumed that mosquito and167
human populations are constant. To model drug resistance, a treated human168
population is required, so we allow infections be to treated at a rate rx, see169
Figure 1.170
A novel aspect of this model is to follow three distinct infection classes:171
sensitive j = S, partially-resistant j = P , and fully-resistant j = R in both172
the human and mosquito population. Transference between the three classes,173
of the form S → P → R, occurs in the treated population only, via a pro-174
cess we call ‘replacement’. Replacement depends on factors such as the drug175
pressure, the mutation rate, and the de novo hazard. At a practical level176
these factors depend on inadequate dosage levels, poor compliance, combi-177
nation therapy, and other implementation factors. Three different methods178
to quantify the replacement rate, φ, are discussed in Section 4.179
Resistance also occurs in the human population via mosquito transmis-180
sion, which we consider separately since the resistance evolution is not di-181
rectly affected by the transmission intensity (Hastings et al. 2005). Resistant182
infections may not be transmitted as easily, which is included in our model183
via the transmission probabilities bj and cj. The probabilities that a bite184
leads to an infection in a human are related such that bS ≥ bP ≥ bR, and the185
probabilities that a bite leads to an infection in a mosquito are related such186
that cS ≥ cP ≥ cP . This allows the possibility that even when the cost of187
resistance is infinite, and so transmission of fully-resistant infections is zero,188
bR = cP = 0, fully-resistant infections can persist due to the replacement of189
partially-resistant infections within treated hosts. Additionally, even when190
within-host resistance evolution has been removed, φ = 0, resistant infections191
may persist via transmission.192
2.1. Human population193
The total number of humans, which remains constant, is N , and is thus194
the sum of susceptible hosts S, infected hosts Ij and treated hosts Tj (j =195
S, P , R),196
N = S(t) + I(t) + T (t),
where I = IS+ IP + IR and T = TS+TP +TR. The recovery and death rates197
for all untreated infections, and treated fully-resistant infections, are assumed198
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to be the same, (rI and α respectively). Perfect treatment is assumed so that199
the death rate for individuals with sensitive and partially-resistant treated200
infections is the same as the background death rate µ. The recovery rates for201
sensitive and partially-resistant infections are rTS and rTP . Comparing the202
recovery and death rates for the different classes: rI < rTP < rTS and µ < α.203
2.1.1. Infected human population, Ij(t)204
There are three classes of infected humans. For a given infection, the205
population is increased by the susceptible population which are bitten by a206
mosquito in class j, and decreased according to a recovery rate and back-207
ground death rate,208
dIj
dt
= abjm
S
N
Iˆj − (rI + rx + α)Ij, (1)
where a is the biting rate of mosquitoes, m is the density of female mosquitoes,209
and Iˆj is the number of mosquitoes with a class j infection. All variables and210
parameters are defined in Tables 2 and 3.211
2.1.2. Treated human population, Tj(t)212
Infected humans are treated at a rate rx. Within the treated population,213
there is replacement (S → P → R) due to growing resistance, via the214
replacement rate φ,215
dTS
dt
= rxIS − (φ+ µ+ rTS )TS , (2)
dTP
dt
= rxIP − (φ+ µ+ rTP )TP + φTS , (3)
dTR
dt
= rxIR − (α + rI)TR + φTP . (4)
The replacement S → P is assumed to occur at the same rate as P → R216
for ease of analysis, but they could be different rates. Note that IR and TR217
are the same: fully-resistant infections are unaffected by treatment, either218
because treatment was not administered IR or it is ineffective TR. How-219
ever, using separate compartments allows us to monitor for infections that220
were initially partially-resistant TR (establishment), and those that arise from221
mosquito transmission IR (development).222
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2.2. Mosquito population223
The total number of mosquitoes Nˆ remains constant in time,224
Nˆ = Sˆ(t) + Eˆ(t) + Iˆ(t), (5)
and we assume recovery rates and death rates do not vary due to infec-225
tion. There are three classes of mosquitoes to correspond with the sensitive,226
partially-resistant, and fully-resistant infections.227
2.2.1. Exposed mosquito population, Ej(t)228
For a given infection, j = S,P ,R, the population is increased by the229
susceptible population which bite an infectious human in class j. At each230
time interval, a proportion leave the exposed population because the latency231
period τˆ has expired, as well as the background death rate µˆ,232
dEˆj
dt
= acj
Ij + Tj
N
Sˆ − acj
I ′j + T
′
j
N ′
Sˆ ′e−µˆτˆ − µˆEˆj, (6)
where (·)′ is (·) at time t− τˆ .233
2.2.2. Infected mosquito population, Iˆj(t)234
The population is increased from the exposed population whose latency235
period has expired, and decreased according to the background death rate,236
dIˆj
dt
= acj
I ′j + T
′
j
N ′
Sˆ ′e−µˆτˆ − µˆIˆj. (7)
2.3. Example simulations237
The model is run for three years using the values in Table 3, and initially238
no infected humans nor mosquitoes with partially-resistant nor fully resistant239
infections,240
IP = IR = EˆP = EˆR = IˆP = IˆR = 0.
However, there are initially a small proportion of treated humans with the241
more resistant classes. The non-zero compartments at t = 0 are242
S = 99.4, IS = 0.5, TS = TP = TR = 0.099, and Sˆ = 80, EˆS = IˆS = 10. (8)
9
Figure 1: Schematic diagram of our malaria model. Infections are either sensitive j = S,
a partially-resistant j = P or a fully-resistant j = R. Susceptible mosquitoes become
infected in relation to the proportion of infected humans. After a latency period of τˆ ,
mosquitoes become infectious and may infect susceptible humans. Infections in humans
are treated at rate rx. In the human population, each compartment has a down arrow to
represent death, at either the background rate µ, or the rate due to infection α (µ < α).
The up arrows represent recovery (rTS < rTP < rI), where all recovered persons become
susceptible again. For clarity, this return to susceptible is not explicitly shown. In the
mosquito population, the up arrow represent death at rate µˆ, where death is replaced by
new susceptible mosquitoes.
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Table 2: Model variables
Epidemiological compartments Symbol
Total number of humans N
Susceptible humans S
Humans with sensitive infection IS
Humans with partially-sensitive infection IP
Humans with fully-resistant infection IR
Total infected humans I
Treated humans with sensitive infection TS
Treated humans partially-sensitive infection TP
Treated humans fully-resistant infection TR
Total number of mosquitoes Nˆ
Susceptible mosquitoes Sˆ
Mosquitoes exposed to sensitive infection EˆS
Mosquitoes exposed to partially-resistant infection EˆP
Mosquitoes exposed to fully-resistant infection EˆR
Total exposed mosquitoes Eˆ
Mosquitoes infected with sensitive infection IˆS
Mosquitoes infected with partially-resistant infection IˆP
Mosquitoes infected with fully-resistant infection IˆR
Total infected mosquitoes Iˆ
11
Table 3: Parameter description and their default values. Unless indicated by a ∗, values
are from Mandal et al. 2011. The values indicated by a ∗ are guesstimates.
Parameter Symbol Value
Natural death rate of humans µ 0.017/365 day−1
Death rate of treated humans (assume perfect treatment) µ 0.017/365 day−1
Death rate of not treated humans α ∗0.17/365 day−1
Natural death rate of mosquitoes µˆ 0.2 day−1
Latent period of mosquito τˆ 11 days
Biting rate a 0.25 day−1
Prob. that a bite transmits a sensitive infection to a human bS 0.3
Prob. that a bite transmits a partially-resistant infection to a human bP 0.28
Prob. that a bite transmits a fully-resistant infection to a human bR 0.2
Prob. that a bite transmits a sensitive infection to a mosquito cS 0.5
Prob. that a bite transmits a partially-resistant infection to a mosquito cP 0.4
Prob. that a bite transmits a fully-resistant infection to a mosquito cR 0.3
Ratio of female mosquitoes to humans m 28
Rate that infected humans receive treatment rx 0.03 day
−1
Average recovery rate of untreated infections rI 0.02 day
−1
Average recovery rate of treated, sensitive infections rTS
∗0.06 day−1
Average recovery rate of treated, partially-resistant infections rTP
∗0.04 day−1
Replacement rate φ ∗1/110 day−1
Despite a very low initial presence of resistance, the proportion of resistant243
infections grows rapidly, but then it appears that an endemic equilibrium is244
reached, see Figure 2a. Whereas when there is no cost of resistance, such that245
bS = bP = bR and cS = cP = cR (Figure 2b), the infected proportion contin-246
ues to increase. The specific requirements for an endemic equilibrium, and247
the effect of the transmission probabilities, is discussed further in Section 3.2.248
As previously mentioned, even when bR = cR = 0, fully-resistant infec-249
tions persist due to the replacement of partially-resistant infections within250
treated hosts, see Figure 2c. This figure also has the rate of replacement set251
to zero after one year. Together with Figure 2d, this shows that resistance252
persists in a population once once the possibility of resistance developing253
within a host is removed.254
3. Results255
Having established the model, and discussed some examples, we present256
some analyses to track the emergence and spread of resistance. In Section 3.1,257
the number of secondary infections arising from a single infection is calcu-258
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(a) All parameters as in Table 3 (bS =
0.3, bP = 0.28, bR = 0.2 and cS =
0.5, cP = 0.4, cP = 0.3).
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(b) All infections equally likely to be
transmitted, bS = bP = bR = 0.3 and
cS = cP = cP = 0.5.
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(c) Fully resistance infections cannot be
transmitted, bR = cR = 0, and within-
host resistance evolution removed after
one year, φ = 0 for t > 365.
(d) Within-host resistance evolution re-
moved after one year, φ = 0 for t > 365.
Figure 2
Example simulations to show the effect of varying transmission probabilities
and within-host evolution. All parameters are as in Table 3, unless
otherwise stated. The colours correspond to the compartment colours in
Figure 1: Pink compartments are the infected populations, without
treatment, and the blue compartments are the treated population. Except
the darkest pink, which is the treated population with the fully resistant
infection (this compartment is equivalent to the fully-resistant infected
population without treatment, second darkest pink). The darker tone
correspond to more resistant infections.
lated. By keeping the three classes of infections separate, we focus on the259
number of resistant infections that arise from a sensitive infection. The affect260
of the different treatment variables is discussed, and the importance of the261
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replacement rate φ is quantified. Then we discuss the requirements for an262
endemic equilibrium.263
The importance of φ is verified for two model adaptations, which would264
make the model more realistic. Firstly, in Subsection 3.3, we show that265
the results remain the same when an asymptomatic human population is266
included. Secondly, in Subsection 3.4, we show that as more levels of resis-267
tance evolution are included, the replacement rate φ actually becomes more268
important.269
3.1. Reproductive numbers270
As resistance grows, so does the total number of infected individuals. The271
reproductive number is a measure of the number of secondary, infectious,272
infections expected after one new infection. The number of infections of any273
class, arising from a single infection of any class, is denoted by RS P R→S P R274
and is the sum of275
RIS→IˆSRIˆS→IS
RIS→TS→IˆSRIˆS→IS
}
RS→S , (9)
RIP→IˆPRIˆP→IP
RIP→TP→IˆPRIˆP→IP
}
RP→P , (10)
RIR→IˆRRIˆR→IR
RIR→TR→IˆRRIˆR→IR
}
RR→R, (11)
RIS→TS→TP→IˆPRIˆP→IP
}
RS→P , (12)
RIP→TP→TR→IˆRRIˆR→IR
}
RP→R, (13)
RIS→TS→TP→TR→IˆRRIˆR→IR
}
RS→R, (14)
where the subscripts indicate the movement of the initial infection through276
the different compartments. For example, infection of class j in a mosquito277
passed to a human is RIˆj→Ij . The reproductive numbers (12)–(14) relate to278
resistance emerging, with (14) being of particular interest as it relates to the279
number of fully resistant infections arising from a single sensitive infection.280
Once fully resistant infections are established, the reproductive number (11)281
relates to the fully resistant infection spreading. From the model, (9)–(14)282
are defined as,283
RS→S =
a2bScSm
µˆ
[
rTS + rx + φ+ µ
(rI + rx + α)(rTS + φ+ µ)
]
e−µˆτˆ , (15)
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RP→P =
a2bPcPm
µˆ
[
rTP + rx + φ+ µ
(rI + rx + α)(rTP + φ+ µ)
]
e−µˆτˆ , (16)
RR→R =
a2bRcPm
µˆ
[
1
rI + α
]
e−µˆτˆ , (17)
RS→P =
a2bPcPm
µˆ
[
rxφ
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)
]
e−µˆτˆ , (18)
RP→R =
a2bRcPm
µˆ
[
rxφ
(rI + rx + α)(rTP + φ+ µ)(rI + α)
]
e−µˆτˆ , (19)
RS→R =
a2bRcPm
µˆ
[
rxφ
2
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)(rI + α)
]
e−µˆτˆ .(20)
The derivation of (15)–(20) is provided in Appendix A. The terms outside284
the square brackets relate to the reproductive number of the delay Ross-285
McDonald model,286
RS =
a2bcme−µˆτˆ
µˆ
, (21)
(Ruan et al. 2009). That is, reduction in transmission is most strongly af-287
fected by the exponent terms: the death rate of mosquitoes µˆ, and the latency288
time period τˆ ; the biting rate a has a stronger affect than the transmission289
probabilities b, c (here bj, cj) and the mosquito density m. These known af-290
fects have more impact for the reproductive numbers (15)–(20) which have a291
larger term inside the square brackets. This is especially true for the variables292
to the left of the square brackets, which relate to transmission rates, because293
the terms in the square brackets are of the same order as the transmission294
terms, whereas the latency period and mosquito death rate are exponents.295
We now investigate when the reproductive numbers relating to resistance296
emerging (18)–(20) are large for varying parameters, and thus informing when297
the transmission rates and latency period have a stronger effect on the spread298
of resistance.299
Let us assume that the recovery rate from infection rI , the death rate300
from infection α and background death rate µ are fixed. Therefore, the301
reproductive numbers (15)–(20) only vary by the treatment variables:302
• the recovery rates for sensitive and partially-resistant infections which303
are being treated, rTS , rTP . It is assumed that these rates range between304
2 and 10 times larger than the recovery rate of non-treated individu-305
als rI ,306
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• the rate of infections being replaced by more resistant infections φ ∈307
[0, 1],308
• the treatment rate rx ∈ (0, 1];309
and the cost of resistance, represented by the transmission probabilities bj310
and cj. Overall, the number of infections can be reduced by increasing the311
treatment rate rx and increasing the recovery rates, rTS and rTP . However,312
as the replacement rate φ increases, so does the total number of infections,313
see Figure 4a.314
Previous studies confirm that increasing the rate of treatment increases315
the rate of resistance spread (Koella and Antia 2003, Esteva et al. 2009,316
Chiyaka et al. 2009); and increasing the cost of resistance reduces the spread317
of resistance (Koella and Antia 2003, Esteva et al. 2009). However, like318
Tchuenche et al (2011) and Tumwiine et al. (2014) who include resistance319
growth, we show that the replacement rate has a much stronger affect, see320
Figure 3. Moreover, by including partial resistance in the mosquito popula-321
tion, we can separate resistant infections that are transmitted and those that322
develop within the host.323
When the replacement rate is high, there are a lot of secondary fully-324
resistant infections arising from a single sensitive infection, RS→R. This is325
because the development of fully-resistant infections from sensitive infections,326
RS→R, is affected by the replacement rate twice, hence equation (20) is O(φ2),327
which is the same order as the biting rate a. Therefore, in this model, the328
replacement rate has an equal affect as the biting rate. Since the replacement329
rate φ and the transmission variables a, bj, cj and m are of similar order,330
in areas of high transmission, reducing the replacement rate has a strong331
effect. Moreover, this is actually more effective than reducing the treatment332
rate rx, or increasing the cost of resistance bj, cj, at mitigating resistance333
spread. The limited effect of transmission rates bj and cj is in agreement334
with Gandon et al. (2001, 2003), where they showed that vaccines limiting335
transmission have little effect on evolution.336
Nonetheless, one must be careful when interpreting the specifics of this337
model. For example, treatment rate per day is likely to be considerably338
larger than the replacement rate per day. Under this model, there is reason339
to believe that under certain conditions, the treatment rate may actually340
create more resistance emergence than the replacement rate (for example, the341
treatment rate is rx = 0.9 and the replacement rate is φ = 0.01, see Figure342
4b). However, as we discuss later in Section 3.4, only including one step to343
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resistance is perhaps still too coarse a lens, which would make this example344
meaningless. Instead, when interpreting the resistance emerging reproductive345
number RS→R, consider the overall result that whilst the influence of the346
replacement rate is compounded, the treatment rate and transmission rates347
remain unchanged.348
All resistance emerging reproductive numbers, RS→P , RP→R, RS→R, (15)–349
(20) are inversely related to the treatment rates rTS and rTP . Therefore,350
improved recovery rates not only reduce the overall number of infections,351
but it is especially beneficial for reducing the emergence of drug resistance.352
Note that RS→P , RP→R, RS→R, (15)–(20) depend on the treatment rate of353
partially-resistant infections rTP , whereas the treatment rate of sensitive in-354
fections rTS affects RS→P and RP→R only. Therefore the recovery rate of355
partially-resistant infections is of more importance at mitigating the spread356
of resistance. In fact, the recovery rate of partially-resistant infections rTP357
has a stronger affect than the treatment rate rx, see Figure 4a.358
3.2. Equilibrium359
When considering the disease free equilibrium, we consider the case of a360
constant human population. Without treatment, the system reduces to the361
delay Ross-McDonald model, and thus the disease free equilibrium is trivial.362
The endemic equilibrium is363
I∗
N
=
RS − 1
RS + ace−µˆτˆ/uˆ
,
where RS is as in (21), from Ruan et al. 2009. For the full model presented364
here, with treatment and resistance, the disease free equilibrium is when365
I∗j =
βj
rI + rx + α
,
T ∗S =
rxβS
(rI + rx + α)(rTS + φ+ µ)
,
T ∗P =
rx [φβS + (rTS + φ+ µ)βP ]
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)
,
T ∗R =
rx [φ
2βS + φ(rTS + φ+ µ)βP + (rTS + φ+ µ)(rTP + φ+ µ)βR]
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)(rI + α)
,
where βj = abjm(S
∗/N)Iˆ∗j . As expected, when βS = βP = βR = 0, the366
equilibrium is the disease free equilibrium. These conditions are not met in367
the examples in Figure 2, but it is clear that the difference is negligible.368
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Figure 3
The change in the resistance emerging reproductive numbers RS→P , RP→R
and RS→R, and the overall reproductive number RS P R→S P R, relative to
the recovery rate of the treated population rT , the treatment rate rx, and
the replacement rate φ. The * in the legend indicates the lines are the
same.
We now discuss the conditions required for an equilibrium where only the369
sensitive, and partially-resistant infections are present,370
IR = TR = IˆR = 0. (22)
If fully-resistant infections are absent from IR and IˆR, they can only enter371
the population via TP . Therefore the equilibrium (22) will only remain stable372
if there is no movement from TP to TR. From (19), and assuming that the373
death and recovery rates are non-zero, α, rI > 0, it is clear that movement374
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from TP to TR is only prevented if the treatment or replacement rate is zero,375
rx = 0 or φ = 0. Similarly, the conditions for sensitive only infections is only376
stable under the same conditions. Moreover, even when the cost of resistance377
prevents transmission of the fully-resistant infection, this class of infection378
persists unless rx = 0 or φ = 0 due to resistance developing within a treated379
host.380
3.3. Including an asymptomatic population381
An infection in a human may be asymptomatic Aj, such that infections382
in humans could transfer S ↔ Aj ↔ Ij → Tj (as well as S ↔ Ij → Tj as383
before), where Aj represents asymptomatic infections. We now discuss how384
the reproductive numbers (15)–(20) change with this added feature.385
With these new compartments, the recovery rate of infections (untreated386
or fully-resistant) rI , is the sum of the recovery rates from infected to sus-387
ceptible rIS and from infected to asymptomatic rIA. Similarly, the recovery388
rates from treated infections rTj , j = S, P , is the sum of the recovery rates389
from treated to susceptible rTjS and from treated to asymptomatic rTjA. This390
change does not alter the reproductive numbers (15)–(20). However, more391
significantly, an asymptotic population adds an exponential term e−(rA+µ)τ ,392
where rA is the recovery rate of asymptotic infections, and τ is the asymptotic393
period. This highlights results consistent with previous models - the period394
of time that humans are infectious is key factor of transmission dynamics395
(Chiyaka et al. 2009).396
3.4. Resistance as a scale397
Consider a model for a single infection without partial-resistance, such398
that fully-resistant infections replace sensitive infections directly. In this cir-399
cumstance the number of secondary fully-resistant infections arising from a400
single sensitive infection, RS→R, would be O(bR), O(cP), O(rx), and O(φ),401
not O(φ2) as in this model. This would have led to the conclusion that402
transmission probabilities, treatment rate, and replacement rate are equally403
important. Alternatively, consider a single infection with n steps towards full404
resistance, where each step is equally likely. Then the number of secondary405
fully-resistant infections arising from one sensitive infection RS→R, would406
be O(bR), O(cP), O(rx), as before, but now O(φn). Therefore, because in-407
fections evolve through different stages before becoming fully-resistant, con-408
trolling this evolution is incredibly important, and much more important409
than transmission probabilities and treatment rate. By modelling resistance410
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emergence as a scale, and not a sensitive–resistant dichotomy, the potential411
of combination therapies to disrupt emergence comes into focus.412
To demonstrate, suppose that a sensitive infection evolves resistance to a413
drug at rate φA, and develops resistance to a partner drug at rate φB. From414
our analysis we observe that the number of fully resistant infections to result415
from a single sensitive infection, RS→R, would be O(φAφB). (Both rates416
relate to within-host evolution, so the conclusion that within-host dynamics417
is the driver of resistance still holds.) In this form it is clear that eliminating418
one step (φA = 0 or φB = 0) prevents full resistance developing.419
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Figure 4
The change in the overall reproductive number and the resistance emerging
reproductive number, relative to changes in the treatment variables. The *
in the legend indicates the lines are the same. Note that as the model
becomes more realistic so as to incorporate additional levels of resistance,
the effect of the recovery rates, rTS , rTP , and treatment rate, rx, remain the
same, but the effect of the replacement rate φ (the red line) increases
dramatically.
4. Parameterising the replacement rate φ420
Having established that the replacement φ is the most important treat-421
ment variable, we discuss three different methods to determine an approx-422
imate value. This value is bounded by 0, meaning no resistance evolution,423
and 1, meaning instant transference from sensitive to resistant.424
4.1. The selection window425
When a treatment is first administered a patient is protected from partially-426
resistant and sensitive infections. Once the drug concentration is below a427
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certain value, the resistant genotypes are no longer inhibited by the drug428
and spreads to replace the original, sensitive infection. This time period429
is referred is referred to as the selection window (Kay and Hastings 2015,430
Hastings, Watkins and White 2002). Let us assume that during this selec-431
tion window, sensitive parasites are ‘replaced’ by partially-resistant parasites,432
and thus φ is connected to the selection window.433
Kay and Hastings (2015) use the selection window to calculate the prob-434
ability, as a function of time, of parasites successfully surviving residual drug435
levels. They show that artmether-lumefantrine and artesunate-mefloquine436
kept the probability of successful emergence (our ‘replacement’) below 10%437
for 10 to 20 days post-treatment. This corresponds to 0.0055 ≤ φ ≤ 0.011.438
Whereas resistance is more likely to occur with DHA piperaquine, which kept439
the probability of successful emergence (‘replacement’) below 40% for 10 days440
post-treatment, φ = 0.05. We use a default value of φ = 1/110 = 0.0091 (see441
Table 3), which lies in the range of a combined artesunate treatment.442
4.2. The probability of resistance443
Day and Read (2016) calculate the probability of resistance, dependent444
on the drug concentration c. This corresponds to φ in our model such that445
φ = 1− e−H(c), (23)
where H(c) is the sum of the de novo hazard and the standing hazard. The446
de novo hazard depends on the rate which resistant mutations appear after447
the start of the treatment, and the probability of escape of any such mutant.448
The standing hazard is the hazard due to a standing population of resistant449
microbes that are already present at the start of treatment. The full equation450
for H(c) is provided in Appendix B. Unlike Hastings, Watkins and White451
(2002), which focuses on the effect of drug pressure only, Day and Read452
(2016) find that sometimes moderate treatment is preferred. Equation (23)453
provides useful insight, but parameterising it remains an open challenge.454
4.3. Within-host modelling455
Lastly, one could model the dynamics within-host (Bushman et al. 2016),456
and interface the two models, as in Legros and Bonhoeffer (2016). In Legros457
and Bonhoeffer (2016), the transmission probability b, depends on the num-458
ber of gametocytes, which is determined by a within-host model. The results459
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from this paper indicate that it would be more important to include the re-460
placement rate. This could be done by considering the erythrocytes infected461
with the sensitive clone, YR, such that462
φ = (1− µy)µmYR, (24)
where  ∈ [0, 1] is the treatment efficacy, and µy is the death rate of infected463
erythrocytes, which are both included in the original Legros and Bonhoeffer464
(2016) model. The new variable µm ∈ [0, 1] relates to the proportion of465
erythrocytes infected with the sensitive clone which evolve to become infected466
with the resistant clone. Replacement rate (24) allows a transference from467
sensitive to resistant erythrocytes that increases as the treatment efficacy468
increases, whilst still allowing for reduction in erythrocytes due to death.469
Of note, as the number of erythrocytes infected with the sensitive clone YR470
changes over time, so does the replacement rate φ.471
5. Discussion472
Generally, previous models which monitor the spread of resistance have473
found that reducing the proportion of people treated is one of the most reli-474
able ways to reduce resistance, which is clearly an undesirable strategy both475
for control and elimination. Our model agrees with this finding, but more476
encouragingly and realistically, reducing the replacement rate has a stronger477
effect at reducing resistance spread. Models which include the evolution of478
drug resistance show that it is important, but omit mosquitoes transmit-479
ting varying infections, so a comparison to the transmission probabilities is480
missing.481
In fact, for a model that considers one partially-resistant class only, the482
effectiveness of this control strategy is directly comparable to the conclusions483
from the original Ross-MacDonald model which found that reducing the bit-484
ing rate of mosquitoes is more effective than reducing density of mosquitoes.485
However, when one considers that resistance is a continuous scale, the evolu-486
tion within-host is the most important factor, which emphasises the potential487
of combination therapies to disrupt emergence.488
The replacement rate φ is not specific to a given drug, but instead it is489
a measure which can be influenced by implementation procedures, such as490
pharmacokinetics, pharmacodynamics, poor adherence or combination ther-491
apy. The parameterisation examples provided in Section 4 could be consid-492
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ered as a single factor of a much more complex system. Whilst reasonably pa-493
rameterising this more complex system may be overreaching, understanding494
the various factors should still be the focus of policy decisions. For example,495
when administering combination therapy, it may be challenging to under-496
standing the different rates of resistance to individual drugs, but because it497
is understood that combination therapy lowers the overall replacement rate,498
it should be the preferred treatment strategy. This focus on keeping evolu-499
tion low by treatment administration protocol is also discussed by Bell and500
MacLean (2016), who present an evo-epidemiological model of antibiotic re-501
sistance. Their work predicts that it should be possible for any antibiotic to502
be effectively evolution-proof, as long as the antibiotic is administered in a503
way that prevents the epidemic spread of resistant lineages.504
6. Conclusion505
As resistance spreads, treatment becomes ineffective. To understand506
drivers of resistance we developed a compartmental model that includes507
partial resistance and full resistance, and we then quantified the number508
of resistant infections that arise from a single sensitive infection. Previous509
models for single infections, where resistance is a dichotomy, find that treat-510
ment rate and the cost of infection to be key factors that contribute to the511
spread of resistance. By including just one intermediary step before full re-512
sistance, in both the human and mosquito population, we demonstrate that513
although these factors are important, the transmission of resistance is actu-514
ally best mitigated by controlling the evolution within a host. This result is515
compounded when one considers that the development to full resistance is516
actually a continuous process. This model can be used in combination with517
other models that are investigating this replacement process, and thus one518
can track how certain factors (such as reducing the selection window) affect519
the transmission dynamics.520
Secondly, provided there is a replacement of sensitive infections with more521
resistant variants, a disease free equilibrium does not exist. Moreover, a522
population with only sensitive or partially-resistant infections is not possi-523
ble. This again highlights the importance of understanding what treatment524
strategies are the most effective at reducing this replacement rate.525
Our work strongly advocates for policies which reduce resistance emerg-526
ing (or to at least act quickly once it has emerged). However, resistance to527
malaria treatment has been observed in Africa, yet it has not been estab-528
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lished. This may be because the model presented here only considers single529
infections, and ignores the dynamics within a mosquito. Notwithstanding530
these additions, the model supports further research into resistance develop-531
ing within hosts.532
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Appendix A. The reproductive numbers657
The disease free equilibrium point is when the human population is658
IS = IP = IR = TS = TP = TR = 0 and S = N,
and the mosquito population is659
EˆS = EˆP = EˆR = IS = IP = IR = 0 and Sˆ = Nˆ = 1.
Consider a single newly infectious mosquito with any class of infection. At660
time t this mosquito has a probability e−uˆt of surviving its infectious period,661
and infects humans at a rate abjmS/N . Hence the total number of humans662
who become infectious, from each class, due to this mosquito during its entire663
infectious period is664
RIˆj→Ij = abjm
S
N
∫ ∞
S
e−uˆt dt
=
abjm
µˆ
(A.1)
A similar process is used to derive the total number of mosquitoes who be-665
come infectious from a human during his/her entire infectious period. How-666
ever, there are several different routes the infection can take, see (9)–(11).667
These different routes are detailed below.668
Appendix A.1. Equation (9): RS→S = (RIS→IˆS +RIS→TS→IˆS )RIˆS→IS669
The expected number of mosquitoes who become infectious with a sensi-670
tive infection, from one human with this infection who is not treated, is671
RIS→IˆS = acSe
−µˆτˆ
∫ ∞
S
e−(rI+rx+α)t dt
= acS
1
rI + rx + α
e−µˆτˆ . (A.2)
And if the human is treated, which occurs at a rate rx, the expected number672
of infectious mosquitoes is,673
RIS→TS→IˆS = acSe
−µˆτˆrx
∫ ∞
S
∫ ∞
S
e−(rI+rx+α)ue−(rTS+φ+µ)t du dt
= acS
rx
(rI + rx + α)(rTS + φ+ µ)
e−µˆτˆ . (A.3)
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Combining with (A.1) gives the total number of secondary sensitive infections674
from one human infected with a sensitive infection,675
RS→S =
a2bScSm
µˆ
[
rTS + rx + φ+ µ
(rI + rx + α)(rTS + φ+ µ)
]
e−µˆτˆ .
Appendix A.2. Equation (10): RP→P = (RIP→IˆP +RIP→TP→IˆP )RIˆP→IP676
The expected number of mosquitoes who become infectious with the677
partially-resistant infection, from one human with this infection who is not678
treated, is the parallel to (A.2). Similarly, if the human is treated, which679
occurs at a rate rx, the expected number of infectious mosquitoes is the680
parallel to (A.3). Therefore, the total number of secondary infected humans,681
with a partially-resistant infection, from one human infected with a partially-682
resistant infection, is683
RP→P =
a2bPcPm
µˆ
[
rTP + rx + φ+ µ
(rI + rx + α)(rTP + φ+ µ)
]
e−µˆτˆ .
Appendix A.3. Equation (11): RR→R = (RIR→IˆR +RIR→TR→IˆR)RIˆR→IR684
The expected number of mosquitoes who become infectious with the fully-685
resistant infection, from one human with this infection who is not treated, is686
the same as (A.2). However, if the human is treated, which occurs at a rate687
rx, the expected number of infectious mosquitoes is688
RIR→TR→IˆR = acPe
−µˆτˆrx
∫ ∞
S
∫ ∞
S
e−(rI+rx+α)ue−(rI+α)t du dt
= acP
rx
(rI + rx + α)(rI + α)
e−µˆτˆ .
Combining with (A.1) gives the total number of secondary infected humans,689
with a fully-resistant infection, from one human infected with a fully-resistant690
infection,691
RR→R =
a2bRcPm
µˆ
1
rI + α
e−(rA+µ)τe−µˆτˆ . (A.4)
Appendix A.4. Equation (12): RIS→TS→TP→IˆPRIˆP→IP692
A human infected with a sensitive infection may infect a mosquito with693
partially-resistant infection. This human would be treated at a rate rx, and694
30
become partially-resistant at rate φ, giving,695
RIS→TS→TP→IˆP = acSe
−µˆτˆrxφ
∫ ∞
S
∫ ∞
S
∫ ∞
S
e−(rI+rx+α)ve−(rT+φ+µ)u
e−(rT+φ+µ)t du dv dt
=
acSµ
λ
rxφ
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)
e−µˆτˆ .
Combining with (A.1) gives the total number of secondary infected humans,696
with a partially-resistant infection, from one human infected with a sensitive697
infection,698
RS→P =
a2bPcSm
µˆ
[
rxφ
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)
]
e−µˆτˆ .
Appendix A.5. Equation (13): RIP→TP→TR→IˆRRIˆR→IR699
A human infected with a sensitive infection may infect a mosquito with a700
partially-resistant infections. This human would be treated at a rate rx, and701
become partially-resistant at rate φ, giving,702
RIP→TP→TR→IˆR = acPe
−µˆτˆrxφ
∫ ∞
S
∫ ∞
S
∫ ∞
S
e−(rI+rx+α)ve−(rT+φ+µ)u
e−(rI+α)t du dv dt
= acP
rxφ
(rI + rx + α)(rTP + φ+ µ)(rI + α)
e−µˆτˆ .
Combining with (A.1) gives the total number of secondary infected humans,703
with a fully-resistant infection, from one human infected with a partially-704
resistant infection,705
RP→R =
a2bRcPm
µˆ
[
rxφ
(rI + rx + α)(rTP + φ+ µ)(rI + α)
]
e−µˆτˆ .
Appendix A.6. Equation (14): RIS→TS→TP→TR→IˆRRIˆR→IR706
A human infected with a sensitive infection may infect a mosquito with707
partially-resistant infection. This human would be treated at a rate rx, be-708
come partially-resistant at rate φ, and then fully-resistant at rate φ, giving,709
RIS→TS→TP→TR→IˆR = acSe
−µˆτˆrxφ2
∫ ∞
S
∫ ∞
S
∫ ∞
S
∫ ∞
S
e−(rI+rx+α)we−(rT+φ+µ)v
e−(rT+φ+µ)ue−(rI+α)t dw du dv dt
= acS
rxφ
2
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)(rI + α)
e−µˆτˆ .
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Combining with (A.1) gives the total number of secondary infected humans,710
with a fully-resistant infection, from one human infected with a sensitive711
infection,712
RS→R =
a2bRcSm
µˆ
[
rxφ
2
(rI + rx + α)(rTS + φ+ µ)(rTP + φ+ µ)(rI + α)
]
e−µˆτˆ .
Appendix B. Day and Read 2016713
The probability of resistance emerging is approximately equal to714
φ = 1− e−H(c),
where H(c) is the resistant hazard,715
H(c) = D(c) + S(c).
The quantity D(c) is the de novo hazard,716
D(c) =
∫ a
S
λ[p(s; c), c] pi[x(s; c), c] ds.
Is is comprised of the integral of the product of λ[p(s; c), c], the rate at717
which resistant mutants appear at time s after the start of treatment, and718
pi[x(s; c), c], the probability of escape of any such mutant.719
The quantity S(c) is the standing hazard - the hazard due to a standing720
population of n resistant microbes that are already present at the beginning721
of treatment,722
S(c) = −n ln(1− pi[x(0; c), c]).
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